PT  - JOURNAL ARTICLE
AU  - Jiang, Jian-Lin
AU  - Chang, Joseph Tung-Chieh
AU  - Huang, Bing-Shen
AU  - Chang, Ting-Yu
AU  - Sung, Pi-Shan
AU  - Wei, Yi-Chia
AU  - Lin, Chien-Yu
AU  - Yeh, Chih-Hua
AU  - Fan, Kang-Hsing
AU  - Liu, Chi-Hung
TI  - Vertebral and Carotid Artery Stenosis after Irradiation Both Raise Ischemic Stroke Risk in Head and Neck Cancer Patients
AID  - 10.1101/2024.05.07.24307026
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.05.07.24307026
4099  - http://medrxiv.org/content/early/2024/05/08/2024.05.07.24307026.short
4100  - http://medrxiv.org/content/early/2024/05/08/2024.05.07.24307026.full
AB  - Purpose To study the risk of ischemic stroke (IS) following carotid (CAS) or vertebral artery stenosis (VAS) in head and neck cancer (HNC) patients after radiation therapy (RT).Methods We included HNC patients who received RT between 2010 and 2023. They underwent regular head and neck imaging monitoring to evaluate cancer recurrence at the department of radiation-oncology and vascular examinations at the department of neurology. Patients were initially divided into nasopharyngeal carcinoma (NPC) and non-NPC groups. The primary outcome was the occurrence of IS after RT, and the secondary outcomes included the development of >50% CAS or >50% VAS after RT. Cox regression and Kaplan–Meier analyses were conducted to compare the outcomes of the study groups. Further analysis was conducted based on the presence or absence of >50% CAS or >50% VAS during the follow-up period.Results Of the 1,423 HNC patients, 19%, 6.8%, and 2.3% developed >50% CAS, >50% VAS, and IS during a 58-month follow-up. Compared with the NPC group, the non-NPC group exhibited a higher incidence of >50% CAS (25.4% vs. 10.7%, p<0.001) and >50% VAS (8.8% vs. 4.3%, p<0.001), but similar risks of IS. In patients with HNC, >50% CAS (adjusted hazard ratio [HR]=3.21, 95% confidence interval [CI]=1.53-6.71), and >50% VAS (adjusted HR=2.89, 95% CI=1.28-6.53) were both the independent predictors of IS. In the patients with NPC, >50% CAS was an independent predictor of anterior circulation IS (adjusted HR=4.39, 95% CI=1.17-16.47). By contrast, >50% VAS emerged as a predictor of posterior circulation IS in both the NPC (adjusted HR=15.02, 95% CI=3.76-60.06) and non-NPC groups (adjusted HR=13.59, 95% CI=2.21-83.46).Conclusion HNC patients with >50% CAS or >50% VAS after RT had an increased risk of IS within their corresponding vascular territory. CAS is a major predictor of IS in NPC patients, whereas VAS is a major predictor of IS in both NPC and non-NPC patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was financially supported by Chang Gung Memorial Hospital (grant nos. CMRPG3M0811, CMRPG381503, CMRPG3C0763, CMRPG3G0261, CFRPG3L0011, and BMRPF99) and the Ministry of Science and Technology of Taiwan (grant nos. 106-2511-S-182A-002-MY2, 108-2314-B-182A-050-MY3, 111-2314-B-182A-133-MY3, NMRPG3M6231-3, NMRPG3G6411-2, and NMRPG3J6131-3).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Ethics Institutional Review Board of Chang Gung Memorial Hospital (202101981B0, 202200464B0, and 202400107B0).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesCAScarotid artery stenosisCIconfidence intervalCTcomputed tomographyCDUcarotid duplex ultrasoundHNChead and neck cancerHRhazard ratioISischemic strokeNPCnasopharyngeal carcinomaMRAmagnetic resonance angiographyMRImagnetic resonance imagingPBTproton beam therapyRTradiation therapyVASvertebral artery stenosisVMATvolumetric modulated arc therapyVSvessel stenosis